Share-based Payment Arrangement, Expense of Jasper Therapeutics, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Jasper Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Jasper Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,424,000, a 29% decline year-over-year.
  • Jasper Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $7,022,000, a 21% increase year-over-year.
  • Jasper Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,619,000, a 27% increase from 2023.
  • Jasper Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,211,000.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Jasper Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,022,000 $1,424,000 -$574,000 -29% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $7,596,000 $1,817,000 +$335,000 +23% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $7,261,000 $1,811,000 +$642,000 +55% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $6,619,000 $1,970,000 +$812,000 +70% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $5,807,000 $1,998,000 +$603,000 +43% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $5,204,000 $1,482,000 +$91,000 +6.5% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $5,113,000 $1,169,000 -$98,000 -7.7% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $5,211,000 $1,158,000 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $1,395,000 -$2,696,000 -66% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $1,391,000 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $1,267,000 +$1,167,000 +1167% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q3 2022 $4,091,000 +$3,896,000 +1998% 01 Jul 2022 30 Sep 2022 10-K 05 Mar 2024 2023 FY
Q1 2022 $100,000 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q3 2021 $195,000 -$121,000 -38% 01 Jul 2021 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q3 2020 $316,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3

Jasper Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,619,000 +$1,408,000 +27% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $5,211,000 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2021 $4,000 01 Jan 2021 31 Dec 2021 10-K 18 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.